Neutralizing antibodies to IFN-β, in addition to Myxovirus Resistance Gene A (MxA), have been recommended by the Neutralizing Antibodies on Interferon beta in Multiple Sclerosis consortium along with clinical and imaging studies to make individualized decisions about IFN-β treatment [10]. The gene discussed is IFNB1; the disease is multiple sclerosis.